PTC Therapeutics (NASDAQ:PTCT) Releases Quarterly Earnings Results, Beats Estimates By $0.68 EPS

PTC Therapeutics (NASDAQ:PTCT) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.68, Zacks reports. PTC Therapeutics had a negative net margin of 22.58% and a negative return on equity of 362.45%. The company had revenue of $360.52 million for the quarter, compared to analysts’ expectations of $298.63 million. During the same quarter in the previous year, the business posted ($0.83) EPS. PTC Therapeutics’s revenue was up 101.5% compared to the same quarter last year.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Record results and raised guidance: Second-quarter total revenue reached $361 million, including $239 million in product revenue, prompting PTC to raise 2026 product revenue guidance to $850 million–$950 million and total revenue guidance to $1.18 billion–$1.28 billion. Management believes the company may reach cash-flow breakeven in 2026.
• Sephience launch momentum remains strong: Global Sephience revenue grew 21% sequentially to approximately $151 million, with 1,647 patients on commercial therapy by quarter-end and prescriptions from all U.S. centers of excellence. Japan is ramping quickly, while early-access programs in Europe and other regions are expected to contribute more meaningfully in late 2026 and 2027.
• Patient retention and demand metrics support management’s long-term outlook for Sephience: prescription renewal rates exceed 90%, discontinuations are approximately 20%, and uptake spans treatment-naive patients, prior-therapy failures, switches, and multiple disease severities. PTC continues to project a global commercial opportunity exceeding $2 billion.
• Pipeline progress: Novartis has begun enrolling the approximately 770-patient phase III INVEST-HD study of votoplam, while PTC and Novartis plan to discuss the 24-month data with the FDA in the second half of 2026, including potential accelerated approval pathways. PTC also expects to start the PROVE FA study of vatiquinone in the third quarter and advance its NLRP3, DHODH, and MSH3 programs.
• Strong liquidity but ongoing DMD pressure: Cash, equivalents, and marketable securities totaled $2.23 billion after refinancing most 2026 convertible notes with 0% notes due 2031, supporting potential business development activity. However, the Duchenne franchise faces generic pressure on Emflaza, while Translarna sales continue in certain markets despite regulatory and licensing challenges in Europe.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT traded down $7.27 during midday trading on Friday, hitting $68.25. 3,255,994 shares of the company’s stock traded hands, compared to its average volume of 1,470,965. The stock has a market capitalization of $5.66 billion, a price-to-earnings ratio of -29.29, a price-to-earnings-growth ratio of 6.49 and a beta of 0.53. The firm has a fifty day moving average of $77.59 and a 200 day moving average of $72.77. PTC Therapeutics has a 1 year low of $43.17 and a 1 year high of $90.87.

Insider Buying and Selling at PTC Therapeutics

In other news, Director Mary L. Smith sold 15,834 shares of PTC Therapeutics stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $90.00, for a total transaction of $1,425,060.00. Following the transaction, the director owned 21,813 shares in the company, valued at $1,963,170. This trade represents a 42.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Christine Marie Utter sold 19,686 shares of the business’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $75.56, for a total transaction of $1,487,474.16. Following the sale, the chief accounting officer directly owned 70,199 shares of the company’s stock, valued at approximately $5,304,236.44. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 198,662 shares of company stock worth $16,347,994. Insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its stake in shares of PTC Therapeutics by 28.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock worth $368,587,000 after buying an additional 1,077,776 shares during the period. State Street Corp increased its holdings in PTC Therapeutics by 34.2% in the 4th quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock worth $319,497,000 after acquiring an additional 1,071,343 shares in the last quarter. Toronto Dominion Bank raised its stake in PTC Therapeutics by 27.5% during the 4th quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after acquiring an additional 891,690 shares during the period. Morgan Stanley lifted its holdings in PTC Therapeutics by 115.8% during the fourth quarter. Morgan Stanley now owns 905,192 shares of the biopharmaceutical company’s stock valued at $68,758,000 after purchasing an additional 485,775 shares in the last quarter. Finally, Palo Alto Investors LP boosted its position in shares of PTC Therapeutics by 112.2% in the third quarter. Palo Alto Investors LP now owns 862,613 shares of the biopharmaceutical company’s stock worth $52,939,000 after purchasing an additional 456,144 shares during the period.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, up 101.5% year over year and well above the roughly $299 million analyst estimate. Adjusted earnings were $0.92 per share, compared with a consensus estimate of $0.24 and a year-ago loss of $0.83. PTC Therapeutics Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management increased 2026 total-revenue guidance to $1.18 billion-$1.28 billion and product-revenue guidance to $850 million-$950 million. The outlook reflects continued commercial momentum, particularly for Sephience (sepiapterin). PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience generated $151 million in second-quarter revenue, with the company citing broad uptake and geographic expansion. Product revenue totaled $239 million, supporting the case for accelerating commercial growth. Corporate Update and Q2 Results
• Neutral Sentiment: The earnings call and related coverage focus on PTC Therapeutics entering an important execution phase, with investors monitoring Sephience’s launch trajectory, pipeline progress and the company’s ability to convert strong revenue growth into sustainable profitability. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the earnings and guidance beats, the stock has declined, suggesting a sell-the-news reaction or investor concern that strong results were already reflected in the valuation. Reported profitability metrics remain pressured, including a negative net margin, so markets may be demanding further evidence of durable earnings growth. PTC Therapeutics Q2 Key Metrics

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PTCT. Morgan Stanley lifted their target price on shares of PTC Therapeutics from $93.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday. Weiss Ratings cut shares of PTC Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Royal Bank Of Canada raised their price target on shares of PTC Therapeutics from $82.00 to $85.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Cantor Fitzgerald boosted their price objective on shares of PTC Therapeutics from $124.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, July 16th. Finally, Raymond James Financial assumed coverage on PTC Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $108.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, PTC Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $95.75.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.